Use of cytomedins in case of prostatic involvement in chronic prostatitis according to UPOINT classification

Background: chronic prostatitis is a common disease that significantIy influence on the quality of life. Aim: Our aim was to assess the prevaIence of particuIar domains of UPOINT cIassification and determine the efficiency of prostate- selective cytomedins in complex therapy of chronic prostatitis with the predominance of organic component. Materials and methods: a total of 96 patients aged from 24 to 48 years were treated in City clinical hospital named after D.D. Pletnev in 2017-2018 yy. with a previously diagnosed chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The mean duration of the disease was 18.0±6.2 months. The total NIH-CPSI score was 24±7.3 (pain score 9±4.9, urinary score 7±2,7, quality of life 8±2.3), Qmax was l6±4.2 ml/s, prostate volume - 34±12 cc. Leukocyturia in post-massage urine was found in 52 patients (54%). Positive urine culture after prostate massage or positive bacterial semen study were found in 22 patients (23%). Prostate-specific therapy consisted of 20 days of rectal suppositories Vitaprost-forte® followed by oral therapy by Vitaprost® tablet of the same duration. Results: Follow-up examination of 72 patients (75%) was performed after 3 months of therapy. The total NIH-CSPI score decreased to 15.6±5.1 (pain score 6.3±3.8, urinary score 4.6±2.2, quality oflife 4.7±2), Qmax was 16±3.8 ml/s and mean prostate volume was 24±6 cc. The normalization of laboratory parameters was achieved in all cases. Conclusion: using the UPOINT classification allows to optimize the treatment of patients with chronic prostatitis. Use of prostate-specific cytomedins (Vitaprost®) is highly effective in case of prostatic involvement according to the UPOINT classification.

UPOINT, chronic prostatitis, Vitaprost, UPOINT